Flow cytometric analysis of Mouse CD276 expression on BALB/c mouse peritoneal exudates cells. BALB/c mouse peritoneal exudates cells were stained with PE Rat Anti-Mouse F4/80 Antibody and either Alexa Fluor® 488 Rat IgG1, k Isotype Control (left panel) or SDT Alexa Fluor® 488 Rat Anti-Mouse CD276 Antibody (right panel) at 2 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Alexa Fluor® 488 Rat Anti-Mouse CD276 Antibody (MJ18)
Alexa Fluor® 488 Rat Anti-Mouse CD276 Antibody (MJ18)
Price:
Regular price
$100 USD
Regular price
Sale price
$100 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rat |
| Antigen | CD276 |
| Synonyms | CD276 antigen; B7 homolog 3 (B7-H3); Costimulatory molecule; B7h3; Cd276 |
| Location | Membrane |
| Accession | Q8VE98 |
| Clone Number | MJ18 |
| Antibody Type | Rat mAb |
| Isotype | IgG1,k |
| Application | FCM |
| Reactivity | Ms |
| Positive Sample | BALB/c mouse peritoneal exudates cells |
| Purification | Protein G |
| Concentration | 0.5 mg/ml |
| Conjugation | Alexa Fluor® 488 |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1μg per million cells in 100μl volume | Ms |
Background
CD276 (B7-H3) is an immune checkpoint molecule belonging to the B7 family and encodes a type I transmembrane protein. It plays a role in regulating T cell-mediated immune responses. CD276 is highly expressed in various tumor cells and tumor-infiltrating immune cells, aiding tumor cells in evading immune surveillance and promoting tumor proliferation, metastasis, and treatment resistance. Additionally, CD276 is associated with cancer stem cell properties, and its high expression is linked to poor prognosis. Currently, several targeted therapies against CD276, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies, are under development and in clinical trials, showing promising anti-tumor potential.
Picture
Picture
FC
